Autoimmune diseaseImmunology & inflammationRare disease PopPKPKPDExposure-response

Eculizumab exposure in generalized myasthenia gravis

Reference paper ↗

A two-compartment PK model representing eculizumab central and peripheral disposition and cumulative exposure in generalized myasthenia gravis.

Therapeutic
Eculizumab
Modality
Monoclonal antibody
Target
Complement C5
Disease
Generalized myasthenia gravis
Model type
PopPK, PKPD, Exposure-response

Complete model workspace

Checking workspace access…

Parameters
4
States
4
Equations
4
Derived outputs
6

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

REGAIN approved 900/1200 mg IV regimen PK/PD context

How does the eculizumab regimen determine concentration and cumulative exposure over time? Explore this intervention regimen through Central eculizumab concentration, Peripheral eculizumab concentration, Cumulative eculizumab exposure.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–4,369 hour; step 24

InputDefaultAvailable range
Systemic clearance0.0106 L/h0.0053–0.0159 L/h
Central distribution volume2.54 L1.27–3.81 L
Intercompartmental clearance0.251 L/h0.1255–0.3765 L/h
Peripheral distribution volume2.73 L1.365–4.095 L

Expected readouts

Central eculizumab concentration · Peripheral eculizumab concentration · Exposure (AUC) (ug*hour/mL)

Adjustable model parameters

This public explorer exposes 4 curated parameters. Sign in to edit all 4 declared model parameters.

How the model represents the biology

A two-compartment PK model representing eculizumab central and peripheral disposition and cumulative exposure in generalized myasthenia gravis.

How does intravenous eculizumab distribute and accumulate exposure in this release?Intravenous eculizumab enters a central pool, exchanges reversibly with a peripheral pool, undergoes systemic clearance, and contributes central concentration to cumulative exposure.BIOLOGY OVERVIEWHow does intravenous eculizumab distribute and accumulate exposure in thisrelease?IV eculizumabInfusion to central amountCentral exposureEculizumab concentrationPeripheral poolReversible distributionSystemic clearanceCentral concentration lossCumulative exposureCentral concentration integralPRIMARY READOUTSCentral eculizumab concentrationCentral eculizumab concent…Peripheral concentrationPeripheral concentrationCumulative exposureCumulative exposure

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: C5 binding, complement inhibition, neuromuscular-junction biology, gMG clinical response, and sigmoid-Emax pharmacodynamics are not present; this release is PK-only.

Modeled relationships (4)
  • IV eculizumab → Central exposure: IV input (flow)
  • Central exposure ↔ Peripheral pool: distribution (reversible exchange)
  • Central exposure → Systemic clearance: systemic CL (loss)
  • Central exposure → Cumulative exposure: integrates C (production)

Modeled relationships: IV eculizumab to Central exposure: IV input (flow); Central exposure reversibly exchanges with Peripheral pool: distribution (reversible exchange); Central exposure to Systemic clearance: systemic CL (loss); Central exposure to Cumulative exposure: integrates C (production).

Primary readouts: Central eculizumab concentration; Peripheral concentration; Cumulative exposure.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID monteleone_2021_eculizumab_gmg_pkpd.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics